Cart
sales@molnova.com
Brentuximab
CAS No. 2088770-90-3
Brentuximab( —— )
Catalog No. M36683 CAS No. 2088770-90-3
Brentuximab, a chimeric antibody targeting CD30, is a naked antibody to Brentuximab vedotin. It possesses antitumor activity and may be used to study relapsed or refractory Hodgkin's lymphoma.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 617 | In Stock |
|
| 10MG | 846 | In Stock |
|
| 25MG | 1283 | In Stock |
|
| 50MG | 1693 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameBrentuximab
-
NoteResearch use only, not for human use.
-
Brief DescriptionBrentuximab, a chimeric antibody targeting CD30, is a naked antibody to Brentuximab vedotin. It possesses antitumor activity and may be used to study relapsed or refractory Hodgkin's lymphoma.
-
DescriptionBrentuximab is a chimeric antibody targeting CD30. Brentuximab can be used for the research of emerging targeted therapies.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayApoptosis
-
TargetTNF
-
RecptorTNF
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2088770-90-3
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Oh Y, et al. Part II: Prognosis and management. J Am Acad Dermatol. 2021 Nov;85(5):1093-1106.?
molnova catalog
related products
-
SPD304
SPD304 is a selective TNF-α inhibitor and blocks the interaction of TNF and its receptor. SPD304 has an IC50 of 22 μM for inhibiting in vitro TNF receptor 1 binding to TNF-α.
-
Alethine
Alethine (β-Alethine) is a small molecule compound with antitumour activity and is used to treat tumours and infections.
-
TNF-α-IN-9
TNF-α-IN-9 is an NDM-1 inhibitor-3 analog and is a TNF-α inhibitor.TNF-α-IN-9 shows low inhibitory activity.
